EPHA2 and cancer: Non-canonical EphA2 signaling has been associated with driving melanoma cell phenotypes [71], enhanced levels of aggression in gliomas [4], tumor progression in several cancers [4, 12, 52, 62, 64, 72], metastasis [4, 53, 62], and EMT [4, 53, 70].